Progressive dopamine neuron loss in Parkinson's disease: The multiple hit hypothesis

被引:121
作者
Carvey, Paul M.
Punati, Ashok
Newman, Mary B.
机构
[1] Rush Univ, Med Ctr, Dept Pharmacol, Chicago, IL 60612 USA
[2] Rush Univ, Dept Neurosci Program, Chicago, IL 60612 USA
关键词
Parkinson's disease; dopamine neurons; progression multiple hit hypothesis;
D O I
10.3727/000000006783981990
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Animal models have been an essential tool for researchers and clinicians in their efforts to study and treat Parkinson's disease (PD). Thus, the various ways 6-hydroxydopamine is employed, the use of MPTP in rodents and nonhuman primates, the prenatal exposure to bacterial endotoxin, the postnatal exposure to environmental toxins such as paraquat and rotenone, the assessment of dopamine (DA) neurons in genetic knockout mouse, and even the behavioral analysis of fruit flies and worms have added significantly to our knowledge base of PD-or have they? Are these animal models manifesting a true model of PD? Have the 7786 published studies (to date) on PD with animal models led to a clearer understanding of its etiology, treatment, or progression? In this review we critically assess this question. We begin with a succinct history of the major contributions, which have led to the current animal models of PD. We then evaluate the primary issue of the progressive loss of DA neurons, which, except for a few studies, has not been addressed in animal models of PD, even though this is the major pathological characteristic of the disease. Lastly, we discuss the possibility that more than one risk factor for PD may be necessary to develop an animal model that shows synergy-the progressive loss of DA neurons. Thus, the multiple hit hypothesis of PD-that is, the effect of more then one risk factor-may be the start of new era in animal models of PD that is one step closer to mimicking the pathology of PD in humans.
引用
收藏
页码:239 / 250
页数:12
相关论文
共 50 条
[21]   Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease [J].
Brownell, AL ;
Jenkins, BG ;
Isacson, O .
BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (03) :131-140
[22]   Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss [J].
Aarts, Esther ;
Helmich, Rick C. ;
Janssen, Marcel J. R. ;
Oyen, Wim J. G. ;
Bloem, Bastiaan R. ;
Cools, Roshan .
NEUROIMAGE, 2012, 59 (04) :3339-3346
[23]   Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system [J].
Remy, P ;
Doder, M ;
Lees, A ;
Turjanski, N ;
Brooks, D .
BRAIN, 2005, 128 :1314-1322
[24]   The neuroimmune hypothesis in Parkinson's disease [J].
Kuhn, W ;
Muller, T ;
Nastos, I ;
Poehlau, D .
REVIEWS IN THE NEUROSCIENCES, 1997, 8 (01) :29-34
[25]   An Infection Hypothesis of Parkinson’s Disease [J].
Karpenko M.N. ;
Muruzheva Z.M. ;
Pestereva N.S. ;
Ekimova I.V. .
Neuroscience and Behavioral Physiology, 2019, 49 (5) :555-561
[26]   The Endotoxin Hypothesis of Parkinson's Disease [J].
Brown, Guy C. ;
Camacho, Marta ;
Williams-Gray, Caroline H. .
MOVEMENT DISORDERS, 2023, 38 (07) :1143-1155
[27]   Piezoelectric nanogenerators enabled neuromodulation rescued dopaminergic neuron loss in Parkinson's disease [J].
Chen, Ying-Xin ;
Feng, Pei-Jian ;
Zhong, Guangjun ;
Liu, Jia-Hao ;
Jiang, Beibei ;
Harn, Yeu-Wei ;
Zhao, Di ;
Lin, Zhiqun ;
Zhang, Qiming ;
Shen, Qun-Dong .
NANO ENERGY, 2024, 121
[28]   Dopamine agonists in Parkinson's disease [J].
Tintner, R ;
Jankovic, J .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (11) :1803-1820
[29]   Intracerebroventricular dopamine for Parkinson's disease [J].
Devos, David ;
Devedjian, Jean-Christophe ;
Moreau, Caroline .
ONCOTARGET, 2017, 8 (28) :45034-45035
[30]   Natural history of Parkinson's disease: From dopamine to multiple system involvement [J].
Yanagisawa, Nobuo .
PARKINSONISM & RELATED DISORDERS, 2006, 12 :S40-S46